Compare Stocks: ATNM, KRRO, SPRB, and HURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.20 +2.6%	$1.05	$0.74 ▼ $1.74	$37.73M	0.26	145,244 shs	115,006 shs
HURA TuHURA Biosciences	$1.87 -2.1%	$2.12	$0.41 ▼ $3.43	$121.72M	-0.21	205,660 shs	334,271 shs
KRRO Korro Bio	$9.97 +3.4%	$11.95	$5.20 ▼ $55.89	$141.96M	3.13	205,312 shs	112,213 shs
SPRB Spruce Biosciences	$45.42 -0.6%	$51.69	$30.03 ▼ $240.00	$131.37M	3.25	96,256 shs	65,085 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+2.56%	+1.69%	+16.50%	+14.29%	-24.05%
HURA TuHURA Biosciences	-2.09%	-10.53%	-12.62%	-16.52%	-28.08%
KRRO Korro Bio	+3.42%	+4.84%	-18.55%	-31.19%	-78.43%
SPRB Spruce Biosciences	-0.63%	-4.40%	-21.60%	-10.54%	+471.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.20 +2.6%	$1.05	$0.74 ▼ $1.74	$37.73M	0.26	145,244 shs	115,006 shs
HURA TuHURA Biosciences	$1.87 -2.1%	$2.12	$0.41 ▼ $3.43	$121.72M	-0.21	205,660 shs	334,271 shs
KRRO Korro Bio	$9.97 +3.4%	$11.95	$5.20 ▼ $55.89	$141.96M	3.13	205,312 shs	112,213 shs
SPRB Spruce Biosciences	$45.42 -0.6%	$51.69	$30.03 ▼ $240.00	$131.37M	3.25	96,256 shs	65,085 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+2.56%	+1.69%	+16.50%	+14.29%	-24.05%
HURA TuHURA Biosciences	-2.09%	-10.53%	-12.62%	-16.52%	-28.08%
KRRO Korro Bio	+3.42%	+4.84%	-18.55%	-31.19%	-78.43%
SPRB Spruce Biosciences	-0.63%	-4.40%	-21.60%	-10.54%	+471.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	316.67% Upside
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	381.28% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	67.65% Upside
SPRB Spruce Biosciences	2.77	Moderate Buy	$158.33	248.60% Upside

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, SPRB, and HURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$144.00
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$149.00
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	SPRB Spruce Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/17/2026	SPRB Spruce Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$123.00 ➝ $104.00
8/13/2026	SPRB Spruce Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	1.08	N/A	N/A	$1.31 per share	0.92
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
KRRO Korro Bio	$2.38M	61.64	N/A	N/A	$5.46 per share	1.83
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	$39.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	N/A	-114.26%	-68.57%	11/11/2026 (Estimated)
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest ATNM, KRRO, SPRB, and HURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
HURA TuHURA Biosciences	0.20	0.18	0.18
KRRO Korro Bio	N/A	9.55	9.55
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
HURA TuHURA Biosciences	0.62%
KRRO Korro Bio	13.18%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
HURA TuHURA Biosciences	6.06%
KRRO Korro Bio	4.80%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	25	31.44 million	29.32 million	Optionable
HURA TuHURA Biosciences	22	63.73 million	59.87 million	N/A
KRRO Korro Bio	57	14.73 million	14.02 million	No Data
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable

ATNM, KRRO, SPRB, and HURA Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Spruce Biosciences (SPRB), Arcus Biosciences (RCUS)

October 3 at 5:43 PM | theglobeandmail.com

Spruce Biosciences (NASDAQ:SPRB) Stock Rating Reaffirmed as Market Outperform by Citizens Jmp

September 26, 2026 | americanbankingnews.com

Citizens Jmp Reaffirms "Market Outperform" Rating for Spruce Biosciences (NASDAQ:SPRB)

September 24, 2026 | marketbeat.com

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24, 2026 | streetinsider.com

Lake Street initiates coverage of Spruce Biosciences at buy

September 18, 2026 | msn.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

Lake Street Capital Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)

September 17, 2026 | marketbeat.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | businesswire.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28, 2026 | theglobeandmail.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27, 2026 | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

Spruce Biosciences Joins the Russell 3000® Index

June 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, SPRB, and HURA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.20 +0.03 (+2.56%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.21 +0.01 (+0.83%)

As of 10/5/2026 07:17 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

TuHURA Biosciences NASDAQ:HURA

$1.87 -0.04 (-2.09%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$1.87 0.00 (0.00%)

As of 04:00 AM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Korro Bio NASDAQ:KRRO

$9.97 +0.33 (+3.42%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$9.98 +0.01 (+0.15%)

As of 10/5/2026 07:30 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$45.42 -0.29 (-0.63%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$45.42 -0.01 (-0.01%)

As of 04:00 AM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, SPRB, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, KRRO, SPRB, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, KRRO, SPRB, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, SPRB, and HURA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

TuHURA Biosciences NASDAQ:HURA

Korro Bio NASDAQ:KRRO

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, SPRB, and HURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, KRRO, SPRB, and HURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, KRRO, SPRB, and HURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, SPRB, and HURA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

TuHURA Biosciences NASDAQ:HURA

Korro Bio NASDAQ:KRRO

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools